> VPHM – my earlier concern was based on TSH levels from the monotherapy trial. I was surprised, since TSH is commonly, adversely, affected by interferon.<
Understood—I nevertheless thought your post was important enough to reiterate given that the safety data from the combo portion of the trial remain blinded.
I may be barking up the wrong tree, but VPHM’s comments in today’s PR about safety and viral rebound do not exactly inspire confidence.
VPHM CC: One of the questioners asked if the combo portion of the trial saw any new TSH problems (i.e. any TSH cases other than the one in the mono portion of the trial). Answer: No comment at this time.
Market Data 
Markets 
AI
